A blood test for ovarian cancer by UK medical technology company Angle has achieved a 95.1% correct prediction of cancer.
Angle's Pelvic Mass Triage liquid biopsy test was used in a 200-patient study of women with a pelvic mass or ovarian cyst and, by utilising gene analysis and serum biomarkers, achieved higher sensitivity and specificity than any other test available for the same application.

Dr Richard Moore, director of the gynaecologic oncology division at the University of Rochester Medical Center Wilmot Cancer Institute, said the study showed that the PMT test "has the ability to out-perform current clinical practice in accurately discriminating malignant from benign pelvic masses prior to biopsy or surgery".

"The improved accuracy of the test results in a high level of sensitivity as well as a substantial reduction in false positives. The test also offers key additional benefits over existing practice through the gene expression information it provides, which may help to further guide choices for targeted therapy in women with ovarian cancer."

The predictive assay combines the expression levels of nine different genes and four different serum markers, to detect ovarian cancer in women having surgery for an abnormal pelvic mass.

Related share prices
Angle (AGL) share price